A Novel, Pleiotropic Oral Drug Class that Blocks Gut Migration of Activated T Cells
Time: 2:00 pm
day: Day One
Details:
• Antagonists to retinoic acid receptor-alpha (RARα) block the upregulation of α4β7 and CCR9 during T cell activation in mesenteric lymph nodes
• Daily oral dosing of an RARα antagonist inhibits intestinal epithelial damage in a mouse model of colitis. In separate models, inflammatory T-cell migration to the intestinal lining is also suppressed
• Preclinical safety findings for the highly selective RARα antagonist OR-812 support further development
